Skip to content
    SYK
    Earnings call· Sep 2025(Q3 FY25)

    STRYKER CORP SYK

    Oct 30, 2025 Source

    Executive summary

    Stryker Q3 FY25 — Strong Organic Growth and Raised Full-Year Outlook

    Stryker delivered robust Q3 FY25 results, driven by strong organic sales growth across its diverse portfolio and significant adjusted operating margin expansion. The company raised its full-year outlook, reflecting sustained demand and operational momentum, while actively pursuing strategic tuck-in acquisitions to deepen its market presence. Management remains focused on leveraging its strong balance sheet and Mako platform to drive continued growth and shareholder value.

    Highlights

    5

    • Delivered strong organic sales growth of 9.5% against an 11.5% comparable.

    • Achieved double-digit adjusted EPS growth of 11.1%.

    • U.S. organic sales growth of 10.6% with double-digit growth in Vascular, Trauma and Extremities, Neuro Cranial, and Instruments.

    • Record Q3 Mako installations in the U.S. and worldwide, bolstering market leadership.

    • Adjusted operating margin expanded by 90 basis points to 25.6% of sales.

    Concerns

    4

    • Experienced tariff headwinds with an estimated net impact of approximately $200 million for full year 2025.

    • Continued supply chain disruptions affecting the Emergency Care business within Medical.

    • Inari business experienced destocking, which partially offset robust procedural growth.

    • Lower sales in the Communications operating room business due to timing of infrastructure installations.

    Guidance & targets

    7
    CategoryTargetConfidence
    Organic Net Sales Growth
    9.8% to 10.2%
    high materiality
    High
    Adjusted Earnings Per Share
    $13.50 to $13.60
    high materiality
    High
    Adjusted Other Income and Expense
    approximately $415 million
    medium materiality
    High
    Adjusted Effective Tax Rate
    lower end of 15% to 16%
    medium materiality
    High
    Medical Segment Organic Sales Growth
    10%
    medium materiality
    High
    Inari Pro Forma Sales Growth
    double-digit
    medium materiality
    High
    Inari Sales (as part of Stryker)
    approximately $590 million
    medium materiality
    High

    Segment performance

    11
    SegmentRevenueYoYQoQMargin
    MedSurg and Neurotechnology
    Affected by supply disruptions in medical and strong prior-year comparable. Growth led by Neuro Cranial and Instrument businesses internationally, with healthy performances in South Korea and Japan.
    U.S. organic growth: 9.4%International organic growth: 5.1%
    		—8.4%——
    Instruments (U.S.)
    Led by Surgical Technologies (Neptune, SurgiCount, smoke evacuation)
    		—11.5%——
    Endoscopy (U.S.)
    Led by Sports Medicine (double-digit)Core endoscopy (near double-digit)Offset by lower sales in Communications operating room business due to timing of infrastructure installations
    		—7.9%——
    Medical (U.S.)
    Expected to achieve 10% organic sales growth for the year despite supply chain disruptions affecting emergency care business.
    Acute Care business (ProCuity, Vocera) double-digit performance
    		—6.5%——
    Vascular (U.S.)
    Organic sales growth figures do not include Inari.
    Led by recent launches of Surpass Elite flow diverting stent and Broadway aspiration system
    		—13.4%——
    Neuro Cranial (U.S.)
    Led by strong double-digit growth in IBS, Craniomaxillofacial and Neurosurgical businesses
    		—12.9%——
    Orthopedics
    Strong performance from emerging markets internationally. Includes nominal Spinal implant revenue from fulfilling tenders before exiting those markets.
    U.S. organic growth: 12.9%International organic growth: 7.8%
    		—11.4%——
    U.S. Knee
    Reflecting market-leading position in robotic-assisted knee proceduresContinued momentum from new Mako installations
    		—8.4%——
    U.S. Hip
    Highlighted by ongoing success of Insignia Hip StemContinued adoption of Mako robotic hip platform (expanded ability to address more difficult primary hip cases as well as hip revisions)
    		—8.7%——
    U.S. Trauma and Extremities
    Robust double-digit sales growth in Upper Extremities and Core Trauma businessesMultiyear strong Shoulder growth continuesCore Trauma driven by Pangea differentiated plating portfolio
    		—13.2%——
    U.S. Other Ortho
    Driven by robust installationsAmplified by Mako deal mixStrong performance in navigational technology products
    		—38.5%——

    Operational metrics

    9
    Adjusted EPS growth
    11.1%YoY
    Q3 FY25

    Despite tariff headwinds.

    Foreign currency impact on sales
    0.7%favorable
    Q3 FY25
    Foreign currency impact on adjusted EPS
    $0.03favorable
    Q3 FY25
    Adjusted gross margin
    65%50 bps favorable YoY
    Q3 FY25

    Despite tariff headwinds.

    Adjusted operating margin
    25.6%90 bps favorable YoY
    Q3 FY25
    Adjusted other income and expense
    $116M$74M higher than 2024
    Q3 FY25
    Adjusted effective tax rate
    14%
    Q3 FY25
    Inari sales
    $590M
    10 months

    Sales for the 10 months this year as a part of Stryker.

    Operating margin expansion target
    100 bps
    FY25

    Second consecutive year.

    Industry KPIs

    10
    MetricValueDetails
    Tariff impact$200MUSD
    System utilizationhighrates
    Pricing realized price0.4%%
    New product launch ramplaunched
    Procedure volume growthhealthy
    FCF conversion leverage guidance$2.9BUSD
    Installed base system placementsrecordinstallations
    Segment franchise organic growth9.5%%
    Sales force commercial capacity buildsuccessful onboarding
    Pivotal trial clinical evidence milestonesresults expected

    Product announcements

    8
    ProductTypeDetails
    LIFEPAK 35launch
    Surpass Elite flow diverting stentlaunch
    Broadway aspiration systemlaunch
    Insignia Hip Stemupdate
    Pangeaupdate
    Volar plates for distal radiuslaunch
    Mako Shoulderlaunch
    Artixlaunch

    Deals & partnerships

    2
    Guard MedicalAcquisition of NPseal products for negative pressure wound treatment.

    Brings simplified solution for negative pressure wound treatment that strengthens orthopedic instrument offerings. It is a lower cost solution that drops right into the sales bag of orthopedic instrument reps.

    Advanced Medical BalloonsAcquisition of novel patient care products for the Sage business.

    Brings novel patient care products to the Sage business, specifically for fecal incontinence, providing a new product solution for a troubling condition.

    Risks & headwinds

    5
    Tariff headwindsFull year 2025, primarily second half weighted.

    Estimated net impact of approximately $200 million for full year 2025.

    Mitigation: Ongoing focus on margin improvement and cost optimization.

    Supply chain disruptionsOngoing through FY25.

    Affecting the Emergency Care business within Medical, causing it to be lower than it would have been.

    Mitigation: Managing through the disruptions; Medical segment still expected to achieve 10% organic sales growth for the year.

    Inari destockingExpected to be completed by the end of Q1 FY26.

    Partially offsetting robust procedural growth in the teens.

    Mitigation: Actively working through the destocking process, with expected acceleration of growth once completed.

    Communications operating room business timingQ3 FY25 (timing issue).

    Lower sales in Q3 FY25.

    Mitigation: Healthy order book, expected to rebound as infrastructure installations proceed.

    Foot and Ankle softnessQ3 FY25, expected improvement next year.

    Not performing as well as desired.

    Mitigation: Management is 'getting after it' and expects better performance going forward.

    What to watch in Q4 FY25

    5

    Inari destocking impact

    By end of Q1 FY26.
    CurrentPartially offsetting double-digit procedural growth.
    TargetCompletion of destocking.

    Why it matters

    Removal of this drag is expected to accelerate Inari's double-digit growth.

    The stocking will be completed, the burn-through will be completed by the end of the first quarter.

    Q&A highlights

    5

    Seeking insight into global procedure volume trends, health of the capital equipment market, and specific puts/takes in Ortho and Medical segments.

    Kevin Lobo stated that procedure volumes remain very healthy, and capital markets are strong with robust hospital balance sheets supporting outright purchases. He noted that while Communications OR business saw timing delays, the order book is healthy, and Medical, despite supply chain issues in emergency care, is expected to have a strong Q4 and achieve double-digit growth for the year.

    “Procedure volumes are very healthy, which affects, obviously, our implants as well as our small capital. And the capital markets are really strong. The balance sheets are strong with hospitals.”

    asked by Robbie Marcus · answered by Kevin Lobo

    2 min read6 chapters

    Detailed Narrative

    01

    Strong Q3 Performance and Outlook

    Stryker reported strong Q3 FY25 results with 9.5% organic sales growth, building on an 11.5% comparable from the prior year. Adjusted EPS grew 11.1% despite tariff headwinds🌐. The company raised its full-year 2025 guidance for organic net sales growth to 9.8%-10.2% and adjusted EPS to $13.50-$13.60, reflecting continued strong demand and operational momentum.

    02

    Mako and Orthopedics Momentum

    The Orthopedics segment delivered 11.4% organic sales growth, with U.S. Knees up 8.4% and U.S. Hips up 8.7%. The company achieved a record number of Mako installations in Q3, both domestically and internationally, with high utilization rates. Mako's expanded capabilities for primary hip cases and revisions, alongside new product innovations like the Insignia Hip Stem, are driving continued market share gains.

    03

    Inari Integration and Recovery

    The integration of Inari is progressing well, with successful onboarding of sales professionals. The business delivered double-digit pro forma organic sales growth in Q3, driven by robust procedural growth in the teens, though partially offset by destocking. Management expects destocking to conclude by the end of Q1 next year, with Inari on track for double-digit pro forma sales growth in 2025 and approximately $590 million in sales for its 10 months as part of Stryker.

    04

    Capital Equipment and Procedure Volumes

    Procedural volumes remained healthy and in line with expectations in Q3, with anticipated continued strength through year-end. Demand for capital products was strong, leading to an elevated backlog. Hospitals' balance sheets are robust, supporting outright purchases of capital equipment like Mako systems and ProCuity beds, indicating a steady hospital CapEx environment.

    05

    Margin Expansion and Tariff Headwinds

    Adjusted gross margin improved by 50 basis points to 65%, driven by business mix and cost optimization. Adjusted operating margin expanded by 90 basis points to 25.6%. However, tariff headwinds🌐 are significant, with an estimated net impact of approximately $200 million for full year 2025, primarily weighted towards the second half⚖️.

    06

    Strategic M&A and Pipeline

    Stryker completed two small tuck-in acquisitions in Q3: Guard Medical's NPseal products for negative pressure wound treatment and Advanced Medical Balloons for novel patient care products in the Sage business. These deals align with the strategy to deepen the portfolio and enhance growth. The company maintains a healthy deal pipeline and a strong balance sheet, planning to remain active in M&A as a top capital allocation priority.

    AI-generated summary of the company’s earnings call. Not investment advice.